ReviewJournal of geriatric oncology2017
Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
Review in Journal of geriatric oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Perspective recommendations on geriatric support for older adults with multiple myeloma based on challenges faced by a multidisciplinary team.Frontiers in oncology · 2026Article
- Development and validation of a novel frailty model for the patients with newly diagnosed multiple myeloma.European journal of medical research · 2025Article
- Review
- Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.Leukemia · 2020Article
- Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma.BMC cancer · 2020Article
- Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.Clinical interventions in aging · 2020Review
- Management of Newly Diagnosed Elderly Multiple Myeloma Patients.Current oncology reports · 2019Review
- Review
- Balloon kyphoplasty and additional anterior odontoid screw fixation for treatment of unstable osteolytic lesions of the vertebral body C2: a case series.BMC musculoskeletal disorders · 2018Article
- Nrf2: not "lost in translation".Aging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple myeloma increases in incidence with age. With the aging of the population, the number of cases of multiple myeloma diagnosed in older adults each year will nearly double in the next 20years. The novel therapeutic agents have significantly improved survival in older adults, but their outcomes remain poorer than in younger patients. Older adults may be more vulnerable to toxicity of therapy, resulting in decreased dose intensity and contributing to poorer outcomes. Data are beginning to emerge to aid in identifying which individuals are at greater risk for toxicity of therapy; comorbidities, functional limitations, and age over 80years are among the factors associated with greater risk. Geriatric assessment holds promise in the care of older adults with multiple myeloma, both to allow modification of treatment to prevent toxicity, and to identify vulnerabilities that may require intervention. Emerging treatments with low toxicity and attention to individualizing therapy based on geriatric assessment may aid in further improving outcomes in older adults with multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.